WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018067589) ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/067589    International Application No.:    PCT/US2017/054969
Publication Date: 12.04.2018 International Filing Date: 03.10.2017
IPC:
C07D 217/26 (2006.01), A61K 31/5377 (2006.01)
Applicants: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK [US/US]; 412 Low Memorial Library 535 W. 116th Street New York, NY 10027 (US).
NY STATE PSYCHIATRIC INSTITUTE [US/US]; 1051 Riverside Drive New York, NY 10032 (US)
Inventors: RINDERSPACHER, Kirsten, Alison; (US).
YU, Wai; (US).
DUFF, Karen; (US).
LANDRY, Donald; (US).
DENG, Shi-xian; (US)
Agent: HOOPER, Kevin, C.; (US)
Priority Data:
15/480,220 05.04.2017 US
PCT/US2016/055561 05.10.2016 US
Title (EN) ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES
(FR) ACTIVATEURS DE FLUX AUTOPHAGIQUE ET DE PHOSPHOLIPASE D ET CLAIRANCE D'AGRÉGATS DE PROTÉINES COMPRENANT TAU ET TRAITEMENT DE PROTÉINOPATHIES
Abstract: front page image
(EN)The present application discloses compounds which are activators of autophagic flux and pharmaceutical compositions comprising said activators. It further discloses use of said compounds and pharmaceutical compositions in the treatment of neurodegenerative diseases, particularly proteinopathies and tauopathies such as Alzheimer's disease. It further discloses methods of enhancing autophagic flux.
(FR)La présente invention concerne des composés qui sont des activateurs de flux autophagique et des compositions pharmaceutiques comprenant lesdits activateurs. Elle concerne en outre l'utilisation desdits composés et compositions pharmaceutiques dans le traitement de maladies neurodégénératives, en particulier des protéinopathies et des tauopathies telles que la maladie d'Alzheimer. Elle concerne enfin des procédés d'amélioration du flux autophagique.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)